8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Differentiation between immune checkpoint inhibitor‐related and radiation pneumonitis in lung cancer by CT radiomics and machine learning

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Consolidation immunotherapy after completion of chemoradiotherapy has become the standard of care for unresectable locally advanced non‐small cell lung cancer and can induce potentially severe and life‐threatening adverse events, including both immune checkpoint inhibitor‐related pneumonitis (CIP) and radiation pneumonitis (RP), which are very challenging for radiologists to diagnose. Differentiating between CIP and RP has significant implications for clinical management such as the treatments for pneumonitis and the decision to continue or restart immunotherapy. The purpose of this study is to differentiate between CIP and RP by a CT radiomics approach.

          Methods

          We retrospectively collected the CT images and clinical information of patients with pneumonitis who received immune checkpoint inhibitor (ICI) only ( n = 28), radiotherapy (RT) only ( n = 31), and ICI+RT ( n = 14). Three kinds of radiomic features (intensity histogram, gray‐level co‐occurrence matrix [GLCM] based, and bag‐of‐words [BoW] features) were extracted from CT images, which characterize tissue texture at different scales. Classification models, including logistic regression, random forest, and linear SVM, were first developed and tested in patients who received ICI or RT only with 10‐fold cross‐validation and further tested in patients who received ICI+RT using clinicians’ diagnosis as a reference.

          Results

          Using 10‐fold cross‐validation, the classification models built on the intensity histogram features, GLCM‐based features, and BoW features achieved an area under curve (AUC) of 0.765, 0.848, and 0.937, respectively. The best model was then applied to the patients receiving combination treatment, achieving an AUC of 0.896.

          Conclusions

          This study demonstrates the promising potential of radiomic analysis of CT images for differentiating between CIP and RP in lung cancer, which could be a useful tool to attribute the cause of pneumonitis in patients who receive both ICI and RT.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

          Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

            First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

              Background Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. Methods We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. Results Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. Conclusions Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
                Bookmark

                Author and article information

                Contributors
                nidong@szu.edu.cn
                tpxsaxin@163.com
                Journal
                Med Phys
                Med Phys
                10.1002/(ISSN)2473-4209
                MP
                Medical Physics
                John Wiley and Sons Inc. (Hoboken )
                0094-2405
                2473-4209
                27 January 2022
                March 2022
                : 49
                : 3 ( doiID: 10.1002/mp.v49.3 )
                : 1547-1558
                Affiliations
                [ 1 ] National‐Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Health Science Center Shenzhen University Shenzhen China
                [ 2 ] Medical Ultrasound Image Computing (MUSIC) Laboratory Shenzhen University Shenzhen China
                [ 3 ] Marshall Laboratory of Biomedical Engineering Shenzhen University Shenzhen China
                [ 4 ] Department of Radiation Oncology, Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou China
                [ 5 ] Department of Biostatistics and Health Data Science Indiana University School of Medicine Indianapolis Indiana USA
                [ 6 ] Regenstrief Institute Indianapolis Indiana USA
                [ 7 ] Department of Radiology Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou China
                Author notes
                [*] [* ] Correspondence

                Dong Ni, School of Biomedical Engineering, 1066 Xueyuan Avenue, Shenzhen 518055, China.

                Email: nidong@ 123456szu.edu.cn

                Peixin Tan, Department of Radiation Oncology, 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, China.

                Email: tpxsaxin@ 123456163.com

                Article
                MP15451
                10.1002/mp.15451
                9306809
                35026041
                7bef170b-70d2-4bbc-9b8c-056bf4050f11
                © 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 05 November 2021
                : 11 August 2021
                : 28 December 2021
                Page count
                Figures: 5, Tables: 3, Pages: 12, Words: 6445
                Funding
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 61901275
                Funded by: Guangzhou Science and Technology Plan Foundation
                Award ID: 2021‐02‐01‐04‐1002‐0017
                Funded by: Shenzhen University Startup Fund
                Award ID: 2019131
                Funded by: National Key R&D Program of China
                Award ID: 2019YFC0118300
                Funded by: Shenzhen Peacock Plan , doi 10.13039/501100012234;
                Award ID: KQTD2016053112051497
                Award ID: KQJSCX20180328095606003
                Funded by: Medical Scientific Research Foundation of Guangdong Province, China
                Award ID: B2018031
                Award ID: B2020024
                Funded by: National Natural Science Foundation of Guangdong Provincial People's Hospital
                Award ID: 8210032051
                Categories
                Research Article
                QUANTITATIVE IMAGING AND IMAGE PROCESSING
                Research Articles
                Custom metadata
                2.0
                March 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:22.07.2022

                ct radiomics,immune checkpoint inhibitor‐related pneumonitis,lung cancer,machine learning,radiation pneumonitis

                Comments

                Comment on this article